Literature DB >> 16543824

Prion protein gene codon 129 modulates clinical course of neurological Wilson disease.

Stephanie Grubenbecher1, Olaf Stüve, Harald Hefter, Carsten Korth.   

Abstract

The polymorphism in the human prion protein gene at codon 129 (PRNP 129) determines susceptibility to prion disease, and has been associated with early onset and a more severe course of other neurodegenerative disorders. Here, we tested the hypothesis that PRNP is a disease-modifying gene in clinical Wilson disease with a neurological phenotype. Allele frequencies in patients with clinical Wilson disease were not different from those of a healthy German control population, and PRNP 129 genotypes did not result in different serum copper, serum ceruloplasmin, or copper in 24-h urine concentrations. PRNP 129 methionine homozygosity, however, led to significantly more severe neurological symptoms in elderly patients, particularly tremor, supporting the notion that PRNP 129 homozygosity contributes to neuronal vulnerability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16543824     DOI: 10.1097/01.wnr.0000209006.48105.90

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  3 in total

1.  The prion protein M129V polymorphism: longevity and cognitive impairment among Polish centenarians.

Authors:  Ewa Golanska; Monika Sieruta; Elizabeth Corder; Sylwia M Gresner; Anna Pfeffer; Malgorzata Chodakowska-Zebrowska; Tomasz M Sobow; Izabela Klich; Malgorzata Mossakowska; Aleksandra Szybinska; Maria Barcikowska; Pawel P Liberski
Journal:  Prion       Date:  2013-02-13       Impact factor: 3.931

Review 2.  Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes.

Authors:  P de Bie; P Muller; C Wijmenga; L W J Klomp
Journal:  J Med Genet       Date:  2007-08-23       Impact factor: 6.318

3.  Evidence for synergistic effects of PRNP and ATP7B mutations in severe neuropsychiatric deterioration.

Authors:  Nauzer Forbes; Susan Goodwin; Kevin Woodward; David G Morgan; Lauren Brady; Michael B Coulthart; Mark A Tarnopolsky
Journal:  BMC Med Genet       Date:  2014-02-20       Impact factor: 2.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.